| Dokumendiregister | Ravimiamet |
| Viit | REP-1/4002-2 |
| Registreeritud | 04.11.2024 |
| Sünkroonitud | 05.11.2024 |
| Liik | Väljaminev kiri |
| Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
| Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
| Toimik | REP-1/2024 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | European Directorate for the Quality of Medicines & HealthCare |
| Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
| Vastutaja | Signe Leito (RA, Labor) |
| Originaal | Ava uues aknas |
Deletion of the revision of Methylprednisolone hydrogen succinate (1131) from the work programme (Group10B).
page 1 / 3
Q1-4 (3668)
NPA: (47938) Type: (!/list-dropdown)
A10 - Estonia (EE)
Do you agree with the deletion of Methylprednisolone hydrogen succinate (1131) from the
work programme? (47939) Type: (L/list-radio)
Yes
A1
If no, please provide further information. (47940) Type: (T/text-long)
-
page 2 / 3
Remarks: (47941) Type: (T/text-long)
-
Powered by TCPDF (www.tcpdf.org)
page 3 / 3
| Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
|---|---|---|---|---|---|---|
| Farmakopöa töökava asjus | 04.11.2024 | 1 | REP-1/4002-1 | Sissetulev kiri | ra | European Directorate for the Quality of Medicines & HealthCare |